PL8177 shows success as COVID-19 therapy in pre-clinical trials
The drug candidate PL8177 reduced inflammation, protected lung tissue and…
The drug candidate PL8177 reduced inflammation, protected lung tissue and reduced lung fibrosis in pre-clinical models with symptoms of COVID-19.